In what was a fait accompli after a failed outcomes study for Merck's (MRK -0.17%) cholesterol drug Tredaptive, the big pharma giant just announced it was suspending sales of the drug. Motley Fool health-care analyst David Williamson explains the embarrassing situation and what this means for investors.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Merck Pulls the Plug
By Dave Williamson
–
Jan 11, 2013 at 6:26PM
NYSE: MRK
Merck
Market Cap
$205B
Today's Change
(-0.17%) -$0.14
Current Price
$81.68
Price as of June 13, 2025, 3:58 p.m. ET
Tredaptive is getting suspended
David Williamson owns shares of Amarin plc (ADR). Follow him on Twitter @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Merck
MRK
$81.68
(-0.17%)
$0.14
Amarin Plc
AMRN
$13.25
(-0.97%)
$0.13
Abbott Laboratories
ABT
$135.43
(-0.75%)
$-1.02
GSK
GSK
$40.86
(-3.84%)
$-1.63
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Should Investors Buy Merck Stock After These Huge Risks?
Stock Market Crash: 3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now
2 Beaten-Down Stocks to Buy and Hold for a Decade
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Is Merck Stock a Bargain Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.